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Abstract
Plasma phospholipid transfer protein (PLTP) is an important modulator of high-density lipoprotein (HDL) metabolism,
regulating its particle size, composition, and mass. In patients with low HDL and cardiovascular disease (CVD), plasma
PLTP activity is positively correlated with the concentration of HDL particles containing apo A-I but not apo A-II (Lp(A-
1)). We recently completed a study to determine the effect of simvastatin and niacin (S^N) therapy on disease progression/
regression in these patients, and found that this therapy selectively increased Lp(A-I). To determine if PLTP was also
increased with this drug therapy, we measured the PLTP activity in the plasma of 30 of these patients obtained at baseline
and after 12 months of therapy, and compared the changes to a similar group of 31 patients who received placebo for the
drugs. No significant increase in PLTP activity was observed in either group of patients. However, changes in apo A-I and
A-II between these two time points were correlated with the corresponding change in PLTP activity. The correlation
coefficients were r = 0.57 (P = 0.001) and r = 0.43 (P = 0.02) for apo A-I, and r = 0.54 (P = 0.002) and r = 0.41 (P = 0.02) for
apo A-II in the placebo and S^N group, respectively. At baseline, PLTP activity correlated positively with the percent of
plasma apo A-I associated with Lp(A-I) (r = 0.38, P = 0.04) and the amounts of apo A-I in these particles (r = 0.43, P = 0.02).
These relationships persisted in patients who took placebo for 12 months (r = 0.46, P = 0.009 and r = 0.37, P = 0.04,
respectively), but was attenuated in those treated with S^N. These data indicate that S^N-induced increase in Lp(A-I) was
PLTP-independent. It also confirms our previous observation that an interrelationship exists between PLTP and apo-specific
HDL particle subclasses in CVD patients with low HDL, and that this relationship is altered by drug intervention. ß 2001
Elsevier Science B.V. All rights reserved.
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1. Introduction
Human plasma phospholipid transfer protein is a
hydrophobic glycoprotein containing 476 amino
acids with a predicted molecular mass of 54.7 kDa
[1]. In vitro, PLTP mediates the net mass transfer of
phospholipid from very low density lipoproteins
(VLDL) to high-density lipoproteins (HDL) [2,3],
promotes the conversion of HDL into larger and
smaller particles [4,5], and generates pre-L HDL [6].
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PLTP can also enhance the removal of cholesterol
from cholesterol-loaded human skin ¢broblasts [7],
facilitate the transfer of K-tocopherol from HDL
or albumin to oxidized low density lipoprotein
(LDL) and endothelial cells, and prevent rabbit
aortic endothelium dysfunction ex vivo [8]. These
observations suggest that PLTP plays a crucial role
in triglyceride-rich lipoprotein and HDL metabolism,
and may be anti-atherogenic. Indeed, recent studies
with PLTP gene knock-out mice reveal the accumu-
lation of abnormal lipoproteins and hyper HDL ca-
tabolism in these animals [9]. Plasma from mice over-
expressing human PLTP has also been shown to con-
tain more pre-L HDL, and is more e⁄cient in pre-
venting the accumulation of intracellular cholesterol
in macrophages than plasma from wild-type mice
[10].
Elevated plasma LDL cholesterol (LDL-C) and a
reduced level of HDL cholesterol (HDL-C) are two
of the risk factors of cardiovascular disease. Many
intervention trials have shown that reducing LDL-C
can decrease CVD events, slow progression of athe-
rosclerosis, or induce atherosclerosis regression [11^
13]. Thus, guidelines for the prevention and treat-
ment of CVD based on LDL-C levels have been
established [14]. However, the proper management
of CVD in patients who do not have elevated
LDL-C but have reduced HDL-C is less clear. Epi-
demiological evidence suggests that a 1 mg/dl (2^3%)
increment in HDL cholesterol would be associated
with a signi¢cant 2^3% decrement in CVD risk
[15]. Thus, we hypothesize that in CVD patients
with low HDL-C, raising the HDL-C level and the
HDL-C/LDL-C ratio with either lifestyle modi¢ca-
tion or drug therapy would be a potentially e¡ective
treatment strategy. Niacin and statins are the most
commonly used agents for e¡ectively raising HDL-C
and lowering LDL-C, respectively. We therefore per-
formed a clinical trial to determine the e¡ect of sim-
vastatin and niacin on coronary disease progression
and regression in this population of patients. Since
PLTP plays an important role in HDL metabolism,
and may be anti-atherogenic, and since it is not
known how niacin increases HDL, we measured
the PLTP activity in these patients before and after
12 months of drug therapy to determine whether
these drugs regulate PLTP. As simvastatin^niacin
(S^N) signi¢cantly increased HDL particles contain-
ing apolipoprotein (apo) A-I but not A-II (Lp(A-I))
[16], and as we had previously observed a strong
association between baseline PLTP and Lp(A-I) in
these patients [17], we hypothesized that PLTP
would also increase with S^N treatment. We did
not ¢nd any consistent change in PLTP activity
with this combination drug therapy. However, we
obtained further evidence of an interrelationship be-
tween plasma PLTP activity and apo-speci¢c HDL
particle subclass distribution and concentration in
this population of patients before drug treatment,
and that this relationship persisted after placebo
treatment, but disappeared during drug interven-
tion.
2. Materials and methods
2.1. Study patients
This study focuses on a subset of CVD patients
who participated in a clinical trial aimed at assessing
the e¡ects of di¡erent lipid-altering strategies on cor-
onary disease progression/regression [18]. They in-
clude all the 61 patients in the Seattle cohort
randomized to take either simvastatin (10^20 mg)
plus niacin (2^4 g) (S^N, n = 30) or placebo for these
drugs (n = 31). All patients had clinical coronary dis-
ease (prior myocardial infarction, angioplasty, or
positive exercise tolerance test), and all demonstrated
coronary stenosis in one or more vessels by angiog-
raphy. All had low HDL-C (9 0.90 mmol/l or 35 mg/
dl for men and 9 1.03 mmol/l or 40 mg/dl for wom-
en), and normal LDL-C (9 3.75 mmol/l or 145 mg/
dl) as averaged from two visits prior to randomiza-
tion. All were taught a conventional healthy lifestyle
approach to increase their HDL-C. This included
counseling in weight reduction, smoking cessation,
and dietary counseling to reduce saturated fatty
acid intake. Also, professional training in moderate
exercise was provided for four months at a rehabil-
itation facility. The study was approved by the Hu-
man Subjects Review Committee of the University of
Washington, and informed consent was obtained
from all subjects before entering the study. Venous
blood was drawn into EDTA-containing Vacutainer
tubes (Becton-Dickinson, Rutherford, NJ) after a
12^14-h overnight fast. Plasma was promptly sepa-
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rated by low-speed centrifugation at 4‡C and imme-
diately used for lipid and apolipoprotein analysis,
and for HDL particle isolation, or frozen at 370‡C
for PLTP activity measurement.
2.2. Lipoprotein and apolipoprotein measurements
Standard enzymatic methodologies performed on
an Abbott Spectrum Bichromatic Analyzer (Irving,
TX) were used to determine cholesterol, triglyceride,
and phospholipid in plasma and/or fractionated lipo-
proteins [19,20]. Apolipoproteins (apo) A-I, A-II,
and B were measured with a Behring nephelometer
using Behring reagents (Behring Diagnostic, Somer-
ville, NJ) and calibrated with the Northwest Lipid
Research Laboratories calibrator. The HDL particles
containing both apo A-I and A-II (Lp(A-I, A-II))
and those containing apo A-I but no A-II (Lp(A-
I)) were isolated from fresh plasma samples of
29 baseline and 60 treatment samples by established
sequential dextran sulfate, anti-A-II, and anti-A-I
chromatography [21,22]. The distribution of apo
A-I between Lp(A-I) and Lp(A-I, A-II), and the lipid
composition in these particles were determined by
quantifying the apo A-I, cholesterol, triglyceride,
and phospholipid in these particles. HDL subpopu-
lations were separated by size using nondenaturing
gradient gel electrophoresis [23]. Based on clustering
of particle sizes of healthy normolipidemic subjects,
the percentage of particles within four size intervals
(7.0^8.2 nm, 8.2^9.2 nm, 9.2^11.2 nm, and 11.2^17.0
nm) were used to describe the particle size pro¢les of
Lp(A-I) and Lp(A-I, A-II) [24].
2.3. Phospholipid transfer protein activity
The plasma phospholipid transfer activity medi-
ated by PLTP was determined by measuring the
transfer of [14C]phosphatidylcholine from phospho-
lipid liposomes to HDL using an established radio-
assay [25]. Three separate dilutions of each plasma
sample obtained from each patient at baseline and
12 months after drug or placebo intervention were
assayed. Baseline and treatment samples from the
same patient were analyzed within an assay. Aliquots
from three frozen plasma samples with di¡erent
PLTP activities were included in each assay to con-
trol for inter-assay variation.
2.4. Arteriography
At baseline catheterization, eight views of the left
and right arteries were ¢lmed after nitroglycerin and
repeated in the follow-up angiogram 36 months after
the baseline catheterization. The fully-blinded assess-
ment of stenosis change has been described [13]. The
primary arteriographic patient end-point was the
mean change, from initial to ¢nal arteriogram, in
percent stenosis for the worst lesion in each of the
nine proximal coronary segments.
2.5. Statistical analysis
Statistical di¡erences between patient groups were
assessed using the Mann^Whitney U-test. Lipid, apo-
lipoprotein, and PLTP activity levels of each patient
at baseline and after 12 months of intervention were
compared using Wilcoxon matched pair signed rank
test. Spearman rank order correlation analyses were
used to determine association between PLTP activity
and lipoproteins. All analyses were carried out using
statistical software (Stat Soft, Tulsa, OK), and P
values of less than 0.05 (two-tailed) were considered
signi¢cant.
3. Results
The 61 patients in this study consisted of 59 men
and two women in the age range of 38^71 years
(mean age 52 years). Age was not signi¢cantly corre-
lated to PLTP activity among these patients. Also,
PLTP activity did not di¡er signi¢cantly between
diabetics and non-diabetics, smokers and non-smok-
ers, obese (body mass index (BMI)s 27 kg/cm2) and
non-obese patients, and those with and without high
blood pressure, although the sample size for diabetics
(n = 7) and smokers (n = 14) was relatively small. In
contrast, the majority of the patients (41 out of 60)
were overweight with a BMI over 27 kg/cm2. Neither
baseline BMI nor mean proximal percent stenosis
was signi¢cantly correlated with PLTP activity in
these patients. Also, neither baseline PLTP activity
nor PLTP activity measured at 12 months after treat-
ment was correlated with the change in atheroscler-
otic disease progression/regression. Changes in PLTP
activity also did not correlate with disease progres-
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sion/regression. Baseline characteristics, including
coronary risk factors, lipids, lipoproteins and PLTP
activity, did not di¡er signi¢cantly between the pa-
tient group taking placebo and that taking simvasta-
tin and niacin (Tables 1 and 2).
Combination S^N treatment signi¢cantly de-
creased total cholesterol and triglyceride and LDL-
C by 24^39%, and increased both HDL2-C (42%)
and HDL3-C (27%). Consistent with these lipid
changes, plasma apo B decreased 33% while plasma
apo A-I increased 14%. When the HDL particles in a
subset of these patients in each group were isolated
and analyzed, only the apo A-I in Lp(A-I) but not
Lp(A-I, A-II) was increased (Table 2). Despite these
changes in plasma lipoproteins, no consistent change
in PLTP activity was detected in either the placebo
group or the treatment group. Thus S^N selectively
increased Lp(A-I) without a¡ecting PLTP. However,
when changes in PLTP and plasma lipid and apoli-
poproteins between the baseline and treatment sam-
ples of each patient were analyzed, changes in apo
A-I and A-II between these two time points were
correlated with the corresponding di¡erence in
PLTP activity (Fig. 1). The correlation coe⁄cients
were r = 0.570, P = 0.001 and r = 0.428, P = 0.018 be-
tween PLTP and apo A-I, and r = 0.535, P = 0.002
and r = 0.411, P = 0.024 between PLTP and apo
A-II in the placebo and S^N group, respectively.
Table 1
Baseline characteristics of study groups
Variable Placebo (n = 31) Simvastatin+niacin (n = 30)
Mean age (years) 51.9 52.3
Gender (% male) 100.0 93.3
High blood pressure (%) 54.8 36.7
Smokers (%) 22.6 23.3
Cigarettes/day 17.4 18.6
Diabetes (Type II) (%) 16.1a 6.7b
Body mass index (kg/cm2) 29.9 29.4
Previous myocardial infarction (%) 48.4 66.7
Mean proximal % stenosis 34.2 33.6
aFour of the ¢ve diabetics had elevated triglycerides (s 1.7 mmol/l).
bOne of the two diabetics had elevated triglycerides.
Table 2
Baseline lipoprotein and PLTP activity level and 12-month treatment changes
Placebo (n = 31) S^N (n = 30)
Mean þ S.D. (mg/dl) Median (% change) Mean þ S.D. (mg/dl) Median (% change)
Plasma CH 198 þ 35 34.9 194 þ 38 324.3***
Plasma TG 209 þ 112 33.0 194 þ 84 339.3***
LDL CH 126 þ 28 34.9 129 þ 37 332.5***
HDL CH 32 þ 6 6.7* 31 þ 5 25.1***
HDL2 CH 4 þ 2 0 4 þ 1 41.7***
HDL3 CH 28 þ 5 10.0** 28 þ 4 26.7***
Apo A-I 109 þ 14 4.0 107 þ 12 13.9***
Apo A-II 29 þ 5 1.1 29 þ 4 33.3
Apo B 118 þ 24 38.2 116 þ 24 332.7***
PLTP activitya 15 þ 2 0.3 14 þ 2 2.3
Apo A-I in Lp(A-I)b 23 þ 5 0.4 21 þ 8 64.0**
Apo A-I in Lp(A-I, A-II)b 90 þ 6 4.0 87 þ 10 3.1
*, **, *** denote changes between treatment and baseline statistically signi¢cant at P90.05, 0.01, and 0.001, respectively.
aPLTP activity expressed in Wmol/ml per hour.
bValues based on n of 13 in the placebo group and n of 16 in the S^N group.
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At baseline, the HDL particles with and without
apo A-II were separated and quanti¢ed in a consec-
utive subset of 13 plasma samples from the placebo
group and 16 from the S^N-treated group. There was
a positive correlation between PLTP activity and the
percent of plasma apo A-I associated with Lp(A-I)
(r = 0.381, P = 0.041), and the concentration of apo
A-I, cholesterol, and phospholipid in these particles
(r = 0.429, P = 0.020; r = 0.488, P = 0.007; and
r = 0.438, P = 0.018, respectively) (Table 3). Corre-
sponding relationships were not seen with Lp(A-I,
A-II). When a similar analysis was performed on
Fig. 1. Correlation between change in plasma PLTP activity and changes in plasma apo A-I (A,B) and apo A-II (C,D) in CVD pa-
tients treated with placebo (A,C), and combination simvastatin^niacin (B,D).
Table 3
Inter-relationship between PLTP activity and apo-speci¢c HDL particles at baseline and after 12 months of treatment
Treatment
Baselinea (n = 29) Placebo (n = 31) N^S (n = 29)
rs P rs P rs P
% Plasma A-I in Lp(A-I) 0.38 0.041 0.46 0.009 0.29 0.125
Apo A-I in Lp(A-I) 0.43 0.020 0.37 0.040 0.23 0.228
Cholesterol in Lp(A-I) 0.49 0.007 0.40 0.025 0.21 0.279
Phospholipid in Lp(A-I) 0.44 0.018 0.41 0.021 0.29 0.134
Triglyceride in Lp(A-I) 0.07 0.726 0.45 0.011 0.28 0.141
Apo A-I in Lp(A-I, A-II) 0.02 0.917 30.07 0.714 30.03 0.889
Cholesterol in Lp(A-I, A-II) 0.32 0.085 30.31 0.092 30.04 0.823
Phospholipid in Lp(A-I, A-II) 0.09 0.642 30.21 0.257 0.25 0.194
Triglyceride in Lp(A-I, A-II) 30.16 0.423 0.32 0.076 0.20 0.309
aBaseline values based on n of 13 in the placebo group and n of 16 in the S^N group.
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the HDL particles isolated from the 12-month sam-
ples from the 31 placebo-treated patients and 29 S^
N-treated patients, a comparable signi¢cant correla-
tion was seen in the placebo group but not in the S^
N group (Table 3). Hence, under normal physiolog-
ical conditions, plasma Lp(A-I) level and PLTP ac-
tivity in CVD patients with low HDL are interre-
lated. This relationship was attenuated by S^N
treatment.
As PLTP promotes the conversion of HDL into
larger and smaller particles, the correlation between
PLTP activity and HDL size distribution was also
studied. PLTP activity at baseline was not correlated
with the proportion of Lp(A-I) or Lp(A-I, A-II) par-
ticles in any of the four HDL size intervals (7.0^8.2
nm, 8.2^9.2 nm, 9.2^11.2 nm, or 11.2^17.0 nm, re-
spectively). The percentage of Lp(A-I) particles in the
7.0^8.2 nm range (30.3 þ 7.1%) and the 11.2^17.0 nm
range (16.9 þ 4.6%) decreased signi¢cantly to
24.7 þ 7.7% (P = 0.027) and 14.8 þ 5.2% (P = 0.036),
respectively, after 12 months on simvastatin and nia-
cin treatment. In contrast, the proportion of particles
in the 9.2^11.2 nm range increased substantially from
21.5 þ 5.2% to 28.8 þ 9.8% (P = 0.003), while the per-
centage of particles in the 8.2^9.2 nm range did not
change. For Lp(A-I, A-II), the percentage of par-
ticles in the 7.0^8.2 nm range decreased from
42.8 þ 8% to 34.7 þ 6.6% (P = 0.001), whereas the
particles in the 8.2^9.2 nm (42.5 þ 6.4%) and partic-
ularly those in the 9.2^11.2 nm (10.2 þ 2.1%) ranges
increased to 46.7 þ 5.2% (P = 0.036) and 13.4 þ 3.8%
(P = 0.001), respectively. However, the change in
the proportion of Lp(A-I) or Lp(A-I, A-II) particles
in any of the four HDL size intervals was not sig-
ni¢cantly correlated with the change in PLTP activ-
ity.
4. Discussion
In an earlier study, we found that among all plas-
ma lipid and apolipoprotein parameters, plasma
PLTP activity is most strongly correlated with the
percent of total plasma apo A-I associated with
Lp(A-I), and to the concentration of these particles
in a population of CVD patients with low HDL-C
[17]. The patients in that study were the ¢rst 52 con-
secutive patients randomized to participate in a clin-
ical trial aimed at assessing the e¡ects of di¡erent
lipid-altering strategies on CVD progression/regres-
sion. A total of 153 patients (129 from Seattle,
USA and 24 from Vancouver, Canada) in four treat-
ment groups have completed the study. As part of
the protocol of that study, apo-speci¢c HDL par-
ticles were isolated and characterized in the ¢rst
60 baseline blood samples, and all samples obtained
at 12 months after randomization. Of the four treat-
ment groups, we found that only those who received
simvastatin and niacin demonstrated a signi¢cant se-
lective increase in Lp(A-I) particles. Since PLTP ac-
tivity was strongly associated with Lp(A-I) in the
baseline samples of these patients, and since existing
evidence suggests that PLTP plays an important role
in regulating HDL particle concentration, size, and
composition [4,5,9,26^32], we hypothesized that S^N
treatment also increases PLTP. This study focused
therefore only on the group of patients who received
S^N treatment and those who received placebo for
the drugs. Our data show that despite a median in-
crease of 64% in the apo A-I in Lp(A-I), no consis-
tent change in PLTP was detected in response to
S^N treatment. This suggests that the S^N-induced
increase of Lp(A-I) was not related to PLTP. Our
data are consistent with an earlier report which
showed that simvastatin at 20 mg/day did not change
PLTP activity in patients with type IIb hyperlipide-
mia [33]. We now show that the combination of sim-
vastatin and niacin also has no e¡ect on PLTP ac-
tivity.
Although no consistent change in PLTP activity
was observed in either the S^N- or the placebo-
treated groups, variation in PLTP activity was seen
between the baseline and treatment samples. When
changes in PLTP activity were analyzed with the
corresponding lipid and apolipoprotein changes in
each patient between these two time points, we found
that changes in PLTP activity were highly correlated
with changes in apo A-I and A-II. This suggests that
although PLTP is not a major contributor to the
increase of Lp(A-I) in patients treated with S^N, it
does play a modulating role in apo A-I and A-II
metabolism in vivo, as between 17% and 32% of
variation in plasma apo A-I and A-II could be ex-
plained by the variation in PLTP activity in this pa-
tient population.
Our previous report shows that PLTP activity was
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positively correlated with plasma Lp(A-I) in 52 base-
line samples from the patients who participated in
this clinical trial. The baseline data in Table 3 is a
subset of that data, and is consistent with the origi-
nal data set. Of particular interest is the new obser-
vation that this relationship persisted after 12
months of placebo treatment, but was attenuated in
those treated with S^N, con¢rming not only our pre-
vious study, but providing further evidence for an
interrelationship between PLTP and Lp(A-I) under
steady metabolic state. Also, such a relationship was
perturbed by S^N. The observation that PLTP activ-
ity is associated with the partition of plasma apo A-I
between HDL particles with and without apo A-II
suggests a role of PLTP in regulating apo-speci¢c
HDL subclass distribution. It is not clear why plas-
ma PLTP is positively correlated with Lp(A-I) and
its components but not with Lp(A-I, A-II). Even
though we have previously shown that PLTP pro-
motes the conversion of both Lp(A-I) and Lp(A-I,
A-II) to larger and smaller particles in vitro [26], it is
still possible that PLTP preferentially interacts with
Lp(A-I) in vivo. It should be noted that Tahvanainen
et al. [34] reported that serum PLTP activity corre-
lated negatively with the concentration of apo A-I in
Lp(A-I) particles in healthy Finns. The discrepancy
between our observation and Tahvanainen’s report is
unclear, but may be related in part to the di¡erences
in the study populations.
PLTP mass concentration and plasma phospholip-
id transfer activity have been demonstrated to be
elevated in patients with non-insulin-dependent dia-
betes mellitus [35]. Our failure to detect signi¢cant
di¡erences in phospholipid transfer activity between
diabetics and non-diabetics most likely relates to the
relatively small number of diabetics (n = 7) in our
study population. Furthermore, the proportion of
non-diabetic patients with elevated triglyceride (38
of 54 or 70%) was similar to that observed for the
diabetic group (5 of 7 or 71%).
In conclusion, we have demonstrated that in CVD
patients with low HDL-C, simvastatin and niacin
signi¢cantly raise Lp(A-I) levels without any consis-
tent e¡ect on PLTP activity. We have also provided
evidence of the role of PLTP in regulating apo-spe-
ci¢c HDL particle subclass distribution, and that
under normal physiological conditions, an inter-rela-
tionship exists between plasma PLTP activity and the
concentration of Lp(A-I). Furthermore, drug inter-
vention can attenuate this relationship.
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